Alemtuzumab induction is associated with decreased hospitalization rates in pediatric kidney transplant: A UNOS data review for safety and outcomes with common induction regimens
Pediatric Transplantation · 2024
DOI: 10.1111/petr.14783 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, 2024. Verfasst von Emmanuel Aydin-Ghormoz und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Medicine, Albany Medical Center, Albany, New York, USA. Hauptthemen laut MEDLINE: Alemtuzumab, Kidney Transplantation, Hospitalization, Graft Rejection. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: National Science Foundation.
Abstract (Originalsprache)
Background
We hypothesized that alemtuzumab use is safe in pediatric kidney transplant recipients (KTRs) with equivalent long‐term outcomes compared to other induction agents.
Methods
Using pediatric kidney transplant recipient data in the UNOS database between January 1, 2000, and June 30, 2022, multivariate logistic regression, multivariable Cox regression, and survival analyses were utilized to estimate the likelihoods of 1st‐year and all‐time hospitalizations, acute rejection, CMV infection, delayed graft function (DGF), graft loss, and patient mortality among recipients of three common induction regimens (ATG, alemtuzumab, and basiliximab).
Results
There were no differences in acute rejection or graft failure among induction or maintenance regimens. Basiliximab was associated with lower odds of DGF in deceased donor recipients (OR 0.77 [0.60–0.99], p = .04). Mortality was increased in patients treated with steroid‐containing maintenance (HR 1.3 [1.005–1.7] p = .045). Alemtuzumab induction correlated with less risk of CMV infection than ATG (OR 0.76 [0.59–0.99], p = .039). Steroid‐containing maintenance conferred lower rate of PTLD compared to steroid‐free maintenance (HR 0.59 [0.4–0.8] p = .001). Alemtuzumab was associated with less risk of hospitalization within 1 year (OR 0.79 [0.67–0.95] p = .012) and 5 years (HR 0.54 [0.46–0.65] p < .001) of transplantation. Steroid maintenance also decreased 5 years hospitalization risk (HR 0.78 [0.69–0.89] p < .001).
Conclusions
Pediatric KTRs may be safely treated with alemtuzumab induction without increased risk of acute rejection, DGF, graft loss, or patient mortality. The decreased risk of CMV infections and lower hospitalization rates compared to other agents make alemtuzumab an attractive choice for induction in pediatric KTRs, especially in those who cannot tolerate ATG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology and Hypertension, Department of Medicine, Albany Medical Center, Albany, New York, USA.
- Division of Transplant Surgery, Department of General Surgery, Erie County Medical Center, University at Buffalo, Buffalo, New York, USA.
- Schar School of Policy and Government, George Mason University, Arlington, Virginia, USA.
ORCID-Profile: Emmanuel Aydin-Ghormoz, Naoru Koizumi, Meng-Hao Li, Geovani Faddoul
Förderung
- National Science Foundation
Zitieren
APA
Aydin-Ghormoz, E., Ortiz, J., Koizumi, N., Li, M. H., & Faddoul, G. (2024). Alemtuzumab induction is associated with decreased hospitalization rates in pediatric kidney transplant: A UNOS data review for safety and outcomes with common induction regimens. Pediatric Transplantation. https://doi.org/10.1111/petr.14783
Vancouver
Aydin-Ghormoz E, Ortiz J, Koizumi N, Li MH, Faddoul G. Alemtuzumab induction is associated with decreased hospitalization rates in pediatric kidney transplant: A UNOS data review for safety and outcomes with common induction regimens. Pediatric Transplantation. 2024. doi:10.1111/petr.14783
BibTeX
@article{AydinGhormoz2024,
author = {Aydin-Ghormoz, Emmanuel and Ortiz, Jorge and Koizumi, Naoru and Li, Meng-Hao and Faddoul, Geovani},
title = {Alemtuzumab induction is associated with decreased hospitalization rates in pediatric kidney transplant: A UNOS data review for safety and outcomes with common induction regimens},
journal = {Pediatric Transplantation},
year = {2024},
doi = {10.1111/petr.14783}
}
EUVIMED